-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2022
March 29: Held a donation signing ceremony with the Bethune Public Welfare Foundation for the “Constant Learning and Continuous Improvement—Vascular Regenerative Medicine Research” project.
April 8: The subsidiary, BioPharmaceutical, signed a general contracting agreement for the construction of an industrialization project for biopharmaceutical products.
June 2: Subsidiary Huonland obtained the registration certificate for moxifloxacin hydrochloride eye drops.
July 15: The first patient has been enrolled in the Phase IIb trial of the NL005 project.
July 20: PET-CT trial launched at Peking Union Medical College Hospital.
August 16: Signed a cooperation agreement with IQVIA for an NL003 commercialization strategy study.
October 23: A research paper related to NL003 was published in the American Heart Journal.
November 7: NORTHLAND Selected as a Constituent Stock of the North Exchange 50 Index
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005